FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384339985> ?p ?o ?g. }

• W4384339985 abstract "Immune checkpoint inhibition, combined with novel biomarkers, may provide alternative pathways for treating chemotherapy-resistant triple-negative breast cancer (TNBC). This study investigates the expression of new immune checkpoint receptors, including CD155 and CD73, which play a role in T and natural killer (NK) cell activities, in patients with residual TNBC after neoadjuvant chemotherapy (NAC).The expression of biomarkers was immunohistochemically examined by staining archival tissue from surgical specimens (n = 53) using specific monoclonal antibodies for PD-L1, CD155, and CD73.Of those, 59.2% (29/49) were found to be positive (>1%) for PD-L1 on the tumour and tumour-infiltrating lymphocytes (TILs), while CD155 (30/53, 56.6%) and CD73 (24/53, 45.3%) were detected on tumours. Tumour expressions of CD155 and CD73 significantly correlated with PD-L1 expression on the tumour (p = 0.004 for CD155, p = 0.001 for CD73). Patients with CD155 positivity ≥10% were more likely to have a poor chemotherapy response, as evidenced by higher MDACC Residual Cancer Burden Index scores and Class II/III than those without CD155 expression (100% vs 82.6%, p = 0.03). At a median follow-up time of 80 months (range, 24-239), patients with high CD73 expression showed improved 10-year disease-free survival (DFS) and disease-specific survival (DSS) rates compared to those with low CD73 expression. In contrast, patients with CD155 (≥10%) expression exhibited a decreasing trend in 10-year DFS and DSS compared to cases with lower expression, although statistical significance was not reached. However, patients with coexpression of CD155 (≥10%) and low CD73 were significantly more likely to have decreased 10-year DFS and DSS rates compared to others (p = 0.005).These results demonstrate high expression of CD73 and CD155 in patients with residual tumours following NAC. CD155 expression was associated with a poor response to NAC and poor prognosis in this chemotherapy-resistant TNBC cohort, supporting the use of additional immune checkpoint receptor inhibitor therapy. Interestingly, the interaction between CD155 and CD73 at lower levels resulted in a worse outcome than either marker alone, which calls for further investigation in future studies." @default.
• W4384339985 created "2023-07-15" @default.
• W4384339985 creator A5002778711 @default.
• W4384339985 creator A5012785018 @default.
• W4384339985 creator A5015814730 @default.
• W4384339985 creator A5017511721 @default.
• W4384339985 creator A5024766482 @default.
• W4384339985 creator A5045255203 @default.
• W4384339985 creator A5058049313 @default.
• W4384339985 creator A5058962962 @default.
• W4384339985 creator A5066254737 @default.
• W4384339985 creator A5071381729 @default.
• W4384339985 creator A5074202093 @default.
• W4384339985 creator A5082729927 @default.
• W4384339985 creator A5085100148 @default.
• W4384339985 date "2023-07-13" @default.
• W4384339985 modified "2023-10-14" @default.
• W4384339985 title "Diverging prognostic effects of CD155 and CD73 expressions in locally advanced triple-negative breast cancer" @default.
• W4384339985 cites W1552754679 @default.
• W4384339985 cites W1787595709 @default.
• W4384339985 cites W1965225327 @default.
• W4384339985 cites W1980137951 @default.
• W4384339985 cites W2007825988 @default.
• W4384339985 cites W2042711079 @default.
• W4384339985 cites W2072598572 @default.
• W4384339985 cites W2103028860 @default.
• W4384339985 cites W2106190040 @default.
• W4384339985 cites W2113661022 @default.
• W4384339985 cites W2128201178 @default.
• W4384339985 cites W2139727788 @default.
• W4384339985 cites W2266408649 @default.
• W4384339985 cites W2276522360 @default.
• W4384339985 cites W2292051166 @default.
• W4384339985 cites W2345415641 @default.
• W4384339985 cites W2560367415 @default.
• W4384339985 cites W2586318013 @default.
• W4384339985 cites W2591655768 @default.
• W4384339985 cites W2592785733 @default.
• W4384339985 cites W2604710256 @default.
• W4384339985 cites W2626558431 @default.
• W4384339985 cites W2751553129 @default.
• W4384339985 cites W2753155927 @default.
• W4384339985 cites W2769890142 @default.
• W4384339985 cites W2771978163 @default.
• W4384339985 cites W2797470297 @default.
• W4384339985 cites W2809650769 @default.
• W4384339985 cites W2888451395 @default.
• W4384339985 cites W2892839743 @default.
• W4384339985 cites W2902655481 @default.
• W4384339985 cites W2915355467 @default.
• W4384339985 cites W2940599050 @default.
• W4384339985 cites W2950277329 @default.
• W4384339985 cites W2965669274 @default.
• W4384339985 cites W2972170831 @default.
• W4384339985 cites W2979639908 @default.
• W4384339985 cites W2995440672 @default.
• W4384339985 cites W2995903922 @default.
• W4384339985 cites W3000500728 @default.
• W4384339985 cites W3004222930 @default.
• W4384339985 cites W3159104171 @default.
• W4384339985 cites W3159436256 @default.
• W4384339985 cites W3167109368 @default.
• W4384339985 cites W3192745456 @default.
• W4384339985 cites W3201533701 @default.
• W4384339985 cites W3214902428 @default.
• W4384339985 cites W4205542251 @default.
• W4384339985 cites W4224317064 @default.
• W4384339985 cites W4285992810 @default.
• W4384339985 cites W4307810460 @default.
• W4384339985 cites W4310672792 @default.
• W4384339985 doi "https://doi.org/10.3389/fonc.2023.1165257" @default.
• W4384339985 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37519808" @default.
• W4384339985 hasPublicationYear "2023" @default.
• W4384339985 type Work @default.
• W4384339985 citedByCount "0" @default.
• W4384339985 crossrefType "journal-article" @default.
• W4384339985 hasAuthorship W4384339985A5002778711 @default.
• W4384339985 hasAuthorship W4384339985A5012785018 @default.
• W4384339985 hasAuthorship W4384339985A5015814730 @default.
• W4384339985 hasAuthorship W4384339985A5017511721 @default.
• W4384339985 hasAuthorship W4384339985A5024766482 @default.
• W4384339985 hasAuthorship W4384339985A5045255203 @default.
• W4384339985 hasAuthorship W4384339985A5058049313 @default.
• W4384339985 hasAuthorship W4384339985A5058962962 @default.
• W4384339985 hasAuthorship W4384339985A5066254737 @default.
• W4384339985 hasAuthorship W4384339985A5071381729 @default.
• W4384339985 hasAuthorship W4384339985A5074202093 @default.
• W4384339985 hasAuthorship W4384339985A5082729927 @default.
• W4384339985 hasAuthorship W4384339985A5085100148 @default.
• W4384339985 hasBestOaLocation W43843399851 @default.
• W4384339985 hasConcept C121608353 @default.
• W4384339985 hasConcept C126322002 @default.
• W4384339985 hasConcept C143998085 @default.
• W4384339985 hasConcept C203014093 @default.
• W4384339985 hasConcept C204232928 @default.
• W4384339985 hasConcept C2776694085 @default.
• W4384339985 hasConcept C2779786085 @default.
• W4384339985 hasConcept C2780110267 @default.
• W4384339985 hasConcept C502942594 @default.
• W4384339985 hasConcept C530470458 @default.

• next